Donald A. McGovern Jr. - May 19, 2022 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Donald A. McGovern, Jr.
Stock symbol
ATNF
Transactions as of
May 19, 2022
Transactions value $
$16,876
Form type
4
Date filed
5/23/2022, 04:31 PM
Previous filing
Jan 18, 2022
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $16.9K +12.4K +32.5% $1.36 50.6K May 19, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +15K $0.00 15K May 19, 2022 Common Stock 15K $1.36 Direct F2, F3
transaction ATNF Non-Qualified Stock Option (right to buy) Award $0 +134K $0.00 134K May 19, 2022 Common Stock 134K $1.36 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued in consideration for serving on the Board of Directors, as Lead Director, Chairman of the Audit Committee, and as a Member of the Compensation Committee and of the Risk, Safety and Regulatory Committee of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2 Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F3 The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company.
F4 Granted in consideration for serving as Lead Director of the Company during 2021 and 2022 (to date). Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.